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Background. Structured treatment interruption was evaluated in 74 patients who had been pretreated with
antiretrovirals, consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) for 1 year followed by 3 years
of highly active antiretroviral therapy containing a protease inhibitor.
Methods. Patients with a CD4 cell count of 350 cells/mL and a plasma viral load of !50 copies/mL were
randomized to 3 therapy arms: (1) continuous therapy, (2) CD4 cell count–guided theory, and (3) week-on/week-
off (WOWO) therapy. The efficacy and safety of structured treatment interruption and antiretroviral use were
evaluated in human immunodeficiency type 1 (HIV-1)–infected patients. The study end points were percentage
of patients who developed AIDS or who died and a CD4 cell count of 350 cells/mL. Intergroup differences were
analyzed using analysis of variance and Kruskal-Wallis tests.
Results. Baseline characteristics at the start of the structured treatment interruption were similar. At week
48, no patient had died, and 1 patient in the WOWO group had an AIDS-defining condition. The proportions
of patients with a CD4 cell count of 350 cells/mL were 100%, 87%, and 96% in treatment arms 1, 2, and 3,
respectively. The percentages of weeks of antiretroviral use were 100%, 41.1%, and 69.8% in arms 1, 2, and 3,
respectively. The adverse events were not significantly different among arms ( ). Thirty-one percent ofPp .27
patients in the WOWO group experienced virological failure.
Conclusion. WOWO therapy maintained a CD4 cell count of 350 cells/mL in almost all patients but was
associated with high virological failures rates (possibly resulting from previous dual-NRTI therapy), indicating that
this strategy is less useful. Receipt of CD4 cell count–guided therapy resulted in comparable clinical outcomes to
continuous therapy and may save antiretroviral-associated costs, but this needs to be confirmed by a larger trial.
Although combination therapy that involves 3 anti-
retroviral drugs remains the current standard of care
for maintenance of undetectable plasma HIV-1 RNA
levels in HIV-1–infected patients, maintenance of an
adequate CD4 cell count (greater than a level that is
protective against most opportunistic infections) may
provide significant benefits, even if the plasma viral load
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is not suppressed at all times [1]. The use of structured
treatment interruptions may be a viable alternative to
continuous suppression of the plasma viral load by
maintaining an adequate CD4 cell count, saving some
of the costs of antiretroviral therapy, and decreasing a
patient’s overall exposure to antiretrovirals, which can
result in multiple toxicities [2]. Decreases in costs and
in the number of toxicities would be beneficial. This is
a pilot study to evaluate the safety of structured treat-
ment interruptions, because there were little data re-
garding the safety of structured treatment interruptions
when this trial was initiated in 2001. We report data
on the safety of therapy, antiretroviral use, and adverse
events associated with structured treatment interrup-
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tions in HIV-1–infected Thai patients after up to 48 weeks of
study of CD4 cell count–guided and week-on/week-off
(WOWO) therapy approaches, compared with continuous re-
ceipt of antiretroviral treatment.
METHODS
Patients and Study Design
Patients were recruited from the Thai Red Cross Society’s
Anonymous STD/HIV screening clinic and the HIV outpatient
immune clinic of King Chulalongkorn Memorial Hospital
(Bangkok, Thailand). After 226 weeks, a group of 74 patients
who were enrolled in the HIV Netherlands Australia Thailand
Research Collaborative (HIVNAT) 001 trial series (which in-
volved 1 year of dual–nucleoside reverse-transcriptase inhibitor
[NRTI] therapy, followed by 3 years of protease inhibitor–based
HAART) were randomized for this study if their most recent
CD4 cell count was 350 cells/mL and their plasma viral load
had been !50 copies/mL for 6 months [3, 4]. This open-
label, prospective study examined 3 antiretroviral regimen arms
to evaluate 2 structured treatment interruption strategies: con-
tinuous treatment, CD4 cell count–guided treatment, and
WOWO treatment (figure 1). This small sample size limited
our ability to obtain sufficient power to detect a difference
between study arms. The study was approved by the Ethics
Committee of the Faculty of Medicine, Chulalongkorn Uni-
versity (Bangkok). Written informed consent was obtained
from all patients.
Antiretroviral Therapy Regimens for All Treatment Arms
Antiretroviral therapy consisted of saquinavir soft-gel caps
(1600 mg q.d.) boosted with ritonavir (100 mg q.d.) plus 2
NRTIs (standard doses of either zidovudine and lamivudine or
didanosine and stavudine). The NRTI regimen was determined
in the randomization process at the start of the HIVNAT 001
series several years before this structured treatment interruption
trial (table 1).
Management of Antiretroviral Therapy
Continuous and WOWO treatment arms. Patients in the
continuous treatment arm took their antiretrovirals every day.
In the WOWO therapy arm, patients alternated between 1 week
with therapy and 1 week without therapy, and the viral load
was determined at the end of the week that included therapy
to assess whether the patient’s plasma viral load was suppressed.
Commencement of antiretroviral therapy in the CD4 cell
count–guided arm and immunological failure criteria for the
continuous and WOWO arms. The patients in the CD4 cell
count–guided treatment arm began the study while not re-
ceiving therapy and only started antiretroviral therapy if the
CD4 cell count had decreased in accordance with the criteria
noted in table 2. The criteria for commencement or recomm-
encement of antiretroviral therapy in the CD4 cell count–
guided arm are the same as the criteria as for immunological
failure in the continuous and WOWO treatment arms. In the
continuous therapy arm and the WOWO treatment arm, treat-
ment failure was defined as virological failure (i.e., the plasma
viral load was 11000 copies/mL). The criterion of immuno-
logical failure was a decrease in the CD4 cell count to !350
cells/mL or by 30%. Patients in the continuous therapy arm
and the WOWO treatment arm who met these treatment failure
criteria discontinued therapy with once-daily saquinavir soft-
gel caps and switched to continuous therapy with saquinavir
soft-gel caps (1000 mg b.i.d.) and ritonavir (100 mg b.i.d.), in
addition to the same 2 NRTIs. There were no treatment failure
criteria for the CD4 cell count–guided treatment arm.
Cessation of antiretroviral therapy in the CD4 cell count–
guided treatment arm. After receipt of 12 weeks of daily
doses of HAART, patients in the CD4 cell count–guided treat-
ment arm would stop therapy 1 time if the following con-
ditions were met: the CD4 cell count increased to a level that
is greater than the threshold of 50 cells/mL less than the baseline
level (defined as the CD4 cell count at the start of structured
treatment interruption) when the baseline CD4 cell count was
350–399 cells/mL, if the CD4 cell count recovered to350 cells/
mL when the baseline CD4 cell count was 400–500 cells/mL, or
if the CD4 cell count increased to 170% of the baseline level
when the baseline CD4 cell count was 1500 cells/mL.
Patient Monitoring
At each study visit, clinical findings, adverse events, and he-
matological, biochemical, and immunological parameters were
evaluated. Follow-up visits occurred every 12 weeks in the con-
tinuous treatment arm and at weeks 0, 4, and 8 and every 8
weeks thereafter in the CD4 cell count–guided and WOWO
treatment arms. The study period was a maximum of 48 weeks.
Study End Points
The primary end points were progression to AIDS or death.
The secondary end points were proportion of patients with a
CD4 cell count of 350 cells/mL, antiretroviral use, occurrence
of adverse events, and the plasma viral load at the end of the
study period. This study was underpowered as a result of the
limited number of study subjects.
Analysis of Plasma Samples
Plasma HIV-1 RNA levels were assessed with the Roche Am-
plicor HIV-1 Monitor assay, version 1.5, which has a lower
limit of detection of 50 HIV-1 RNA copies/mL. CD4 lympho-
cyte counts were determined by flow cytometry. Resistance se-
quences were analyzed on proviral DNA at the time of treat-
ment failure in WOWO arm.
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Figure 1. Flow chart showing the patients from the time of the start of the The HIV Netherlands Australia Thailand Research Collaborative (HIVNAT)
001 trial to the start of this structured treatment interruption trial. AZT, zidovudine; ddC, zalcitabine; ddI, didanosine; d4T, stavudine; RTV, ritonavir;
SQV-SGC, saquinavir soft-gel caps; STI, structured treatment interruption; 3TC, lamivudine.
Statistical Analysis
Analysis was scheduled when all patients had reached up to
week 48 of follow-up after inclusion in the study. Statistical
calculations were performed using either SAS statistical soft-
ware, version 8.02 (SAS Institute), or SPSS software for Win-
dows, version 9.0 (SPSS). Because this study was developed as
a pilot study, the sample size was not enough to detect a dif-
ference with an a of 0.05 and a power of 0.80 for the primary
end point. The primary analysis involved the percentage of
patients who developed AIDS or died. Secondary analyses in-
volved the percentage of patients with a CD4 cell count of
350 cells/mL, a change in the CD4 cell count over time, the
percentage of days receiving antiretrovirals, the occurrence of
adverse events, and the plasma viral load. Changes in the CD4
cell count were analyzed by a repeated-measurements proce-
dure that used a generalized linear model (PROC MIXED) from
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Table 1. Baseline demographic, treatment, and clinical data for patients before commencement in a









No. of patients at randomizationa 25 23 26
Week of randomizationb
226 17 20 20
230 4 … 4
242 2 3
254 … … 1
262 1 … …
266 1 … 1
Duration of follow-up, median weeks (IQR) 48 (48–48) 48 (48–48) 49 (48–49)
Sex, no. of patients
Male 12 13 11
Female 13 10 15
Age, mean years  SD 34.4  5.7 33.9  6.0 35.5  7.5
Weight, mean kg  SD 55.0  8.7 59.0  11.9 51.5  8.1
HIV-1 RNA level, mean log10 copies/mL  SD 1.70  0.03 1.71  0.04 1.73  0.18
CD4 cell count, median cells/mL (range)
Before commencement of antiretroviral therapy 359 (313–451) 379 (309–428) 328 (281–422)
Before STI trial 653 (595–803) 766 (550–872) 555 (468–779)
NRTIs received, no. of patients
Zidovudine and lamivudine 12 14 15
Didanosine and stavudine 13 9 11
NOTE. The week of randomization indicates when a patient met the eligibility criteria for randomization into this study.
HIVNAT, HIV Netherlands Australia Thailand Research Collaborative; IQR, interquartile range; NRTI, nucleoside reverse-tran-
scriptase inhibitor; WOWO, week-on/week-off.
a Seventy-four of the 87 patients at start of the HIVNAT 001.4 trial were randomized.
b Study weeks refer to the week of HIVNAT trial 001 and correspond to weeks 0, 4, 16, 28, 36, and 40, respectively, of
the present study.
SAS software. All Centers for Disease Control and Prevention
(CDC) clinical events and grade 3 and 4 adverse events, in-
cluding the serious adverse events, were evaluated for safety.
RESULTS
A total of 74 HIV-1–infected Thai patients (36 male and 38
female patients) were randomized to this structured treatment
interruption study. Baseline characteristics, including the CD4
cell count at the start of antiretroviral therapy, are noted in
table 1. The number of patients, age, sex, plasma viral load,
and median CD4 cell count before randomization were well
matched for all treatment arms.
Patients were randomized to a treatment arm as soon as they
were eligible, after finishing the previous once-daily therapy
trial. One can see in table 1 that, although most patients were
randomized 226 weeks after the start of the HIVNAT 001 trial
or at the start of this structured treatment interruption trial,
17 patients did not meet the eligibility criteria until some weeks
later, thus delaying their dates of randomization to this study.
The median duration of patient follow-up after randomization
was 48 weeks for the continuous and CD4 cell count-guided
treatment arms and 49 weeks for the WOWO treatment arm
(table 1).
The proportion of weeks of antiretroviral use over 48 weeks
was 100% (interquartile range [IQR], 100%–100%) in the con-
tinuous treatment arm, 41.1% (IQR, 10.2%–60.7%) in the CD4
cell count–guided treatment arm, and 69.8% (IQR, 50.0%–
98.0%) in the WOWO treatment arm ( for comparisonP ! 001
of all 3 groups and for the CD4 cell count–guided treatment
arm vs. the WOWO treatment arm). The proportion of patients
with a CD4 cell count of 350 cells/mL at the end of follow-
up was 100% in the continuous treatment arm, 87% in the
CD4 cell count–guided arm, and 96% in the WOWO treatment
arm. Only 3 patients in the CD4 cell count–guided treatment
arm had a CD4 cell count of !350 cells/mL at the end of the
study ( for comparison of all 3 treatment arms, byPp .03
Fisher exact test).
In the CD4 cell count–guided treatment arm, 5 patients
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Change in CD4 cell count indicating
that action should be taken Example
350–399 CD4 cell count decreases by 150 cells/mL CD4 cell count decreases from 375 to 310 cells/mL
400–500 CD4 cell count decreases to !350 cells/mL CD4 cell count decreases from 450 to 340 cells/mL
1500 CD4 cell count decreases by 130% from
baseline CD4 cell countb
CD4 cell count decreases from 550 to 370 cells/mL
NOTE. The criteria shown here are the same as the criteria used for determining when to restart antiretroviral therapy in the CD4
cell count–guided treatment.
a Baseline CD4 cell count is CD4 cell count at start of the structured treatment interruption trial.
b For the CD4 cell count–guided treatment arm, if the 30% decrease in CD4 cell count resulted in a CD4 cell count that was still 350
cells/mL, a patient could choose to defer recommencement of antiretroviral therapy until the CD4 cell count was !350 cells/mL.
did not restart antiretroviral therapy during the study. Nine
patients restarted antiretroviral treatment once and subse-
quently ceased receipt of antiretroviral therapy. Of these 9
patients, 4 had to restart antiretroviral therapy 1 more time
before the end of the study. One patient was not receiving
antiretroviral therapy for 3 separate periods during the study.
Finally, 8 patients started receipt of antiretroviral therapy only
once but were receiving treatment at the end of the study.
Eighteen (78%) of 23 patients received 12 weeks of anti-
retroviral re-treatment. Of these 18, all had a plasma viral
load of !500 copies/mL, and 10 had a plasma viral load of
!50 copies/mL after re-treatment. In the CD4 cell count–
guided treatment arm, 47% of patients whose CD4 cell counts
had decreased by 130% chose to not start antiretroviral ther-
apy until their CD4 cell count was !350 cells/mL.
No patient died during the study. At least 1 AIDS Clinical
Trial Group grade 3 or 4 adverse event over the 48-week study
was observed in 11 (44%) of 25 patients in the continuous
treatment arm, 15 (65%) of 23 patients in the CD4 cell count–
guided treatment arm, and 12 (46%) of 26 patients in the
WOWO treatment arm ( ). Comparison of the CD4 cellPp .27
count–guided treatment arm and the WOWO treatment arm
with the continuous treatment arm resulted in P values of .14
and .87, respectively. Only 1 patient, who was randomized to
the WOWO treatment arm, had progression from CDC class
A to class C disease. CDC-classified clinical events included
papular pruritic eruptions in 1 patient, oral hairy leukoplakia
in 1 patient, and esophageal candidiasis occurred in 1 patient,
all of whom were in the WOWO treatment arm. The CD4 cell
counts before the structured treatment interruption for these
3 patients were 1500 cells/mL, and at the time of the diagnoses,
the CD4 cell counts were 350 cells/mL, whereas the plasma
viral load was undetectable in 2 patients and was 49,500 copies/
mL in 1 patient.
Seventeen patients in the continuous treatment arm, 20 pa-
tients in the CD4 cell count–guided treatment arm, and 20
patients in the WOWO treatment arm had been randomized
at the start of this trial and thus had 48 weeks of follow-up
data. Of these patients with 48 weeks of follow-up data, the
median log10 plasma viral loads after 48 weeks were 1.69 copies/
mL (IQR, 1.69–1.69 copies/mL) in the continuous treatment
arm, 1.96 copies/mL (IQR, 1.69–4.12 copies/mL) in the CD4
cell count–guided treatment arm, and 1.70 copies/mL (IQR,
1.69–1.77 copies/mL) in the WOWO treatment arm. The per-
centages of patients in each arm who were randomized im-
mediately and who had undetectable plasma viral loads (i.e.,
!50 copies/mL) after 48 weeks in this structured treatment
interruption study were 100% in the continuous treatment arm,
45% in the CD4 cell count–guided treatment arm, and 72%
in the WOWO treatment arm. The median CD4 cell count for
patients with 48 weeks of follow-up data was 637 cells/mL (IQR,
484–794 cells/mL) in the continuous treatment arm, but it was
547 cells/mL (IQR, 373–596 cells/mL) in the CD4 cell count–
guided treatment arm and 582 cells/mL (IQR, 468–787 cells/
mL) in the WOWO treatment arm. The CD4 cell count de-
creased from the baseline level in all treatment arms, although
the largest decrease in the CD4 cell count occurred in the CD4
cell count–guided treatment arm.
Treatment failure, which is defined in Methods and in table
2 as virological or immunological failure during treatment in
the continuous and WOWO treatment arms, occurred in 8
(31%) of 26 patients in the WOWO treatment arm (7 patients
had a plasma viral load of 11000 copies/mL, and 1 had a CD4
cell count of !350 cells/mL). Of the 7 patients with viremia, no
drug resistance was found in 2 patients; for 4 patients, samples
were not able to be amplified; and virus from 1 patient was
found to have zidovudine resistance (codons 41, 210, and 215)
[5]. None of the patients in the continuous treatment arm
experienced treatment failure. The median time to treatment
failure was 16 weeks after randomization (IQR, 8–32 weeks).
Two patients were lost to follow-up. All patients with treatment
failure had plasma viral loads of !50 copies/mL after a median
time of 12 weeks of continuous twice-daily administration of
antiretrovirals.
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DISCUSSION
This structured treatment interruption trial demonstrates that
adequate immunological function (i.e., a CD4 cell count of
350 cells/mL) may be preserved by use of a CD4 cell count–
guided or WOWO approach to therapy withdrawal and rein-
troduction, compared with continuous antiretroviral therapy.
However, the high rate of virological failure in the WOWO
treatment arm indicates that this strategy may not be useful
for patients who are receiving long-term antiretroviral treat-
ment that includes dual-agent therapy. The rates of adverse
events do not differ among the study arms, although 3 patients
in the WOWO treatment arm had 3 new CDC-defined clinical
events during this period. Significantly fewer antiretrovirals
were used in the CD4 cell count–guided and WOWO treatment
arms, which makes use of this structured treatment interrup-
tion approach worthy of additional study as a cost-saving strat-
egy. In addition, the small sample size increases the likelihood
of b error, because interarm differences may not be apparent,
even if they exist. The short follow-up period could exacerbate
this error. Results of a longer trial that is sufficiently powered
to answer questions about the risks and benefits of structured
treatment interruption are required to confirm our findings
before conclusions can be drawn.
In patients who had 48 weeks of follow-up data, the plasma
viral load was obviously not suppressed in the CD4 cell count–
guided treatment arm, but it was suppressed in 72% of patients
in the WOWO treatment arm. Immunological function was
not preserved as well in the CD4 cell count–guided treatment
arm as in the continuous and WOWO treatment arms. How-
ever, immune system preservation, as indicated by a CD4 cell
count of 350 cells/mL, was found in all patients in the con-
tinuous treatment arm, in 87% of patients in the CD4 cell
count–guided treatment arm, and in 96% of patients in the
WOWO treatment arm. The differences in the pre–structured
treatment interruption CD4 cell counts among treatment arms
and the small cohort size may have been responsible for some
differences between arms in the immunological and virological
comparisons.
The high rate of treatment failures in the WOWO treatment
arm may have been due to the occurrence of undetected mu-
tations during previous suboptimal dual-NRTI antiretroviral
therapy (for first year of antiretroviral treatment) or long-term
HAART exposure (for the 3 years immediately preceding this
structured treatment interruption study), even though only 1
patient was found to have resistance mutations. The WOWO
approach was also problematic for the Staccato international
structured treatment interruption trial [6], which measured the
plasma viral load after the week without therapy, whereas our
study checked the plasma viral load after the week with therapy.
The 31% rate of failure in the WOWO treatment arm in our
study may have been higher if the plasma viral load had been
measured after the week without therapy. A small sample size
and the lower median CD4 cell count in this treatment arm
may have also affected the percentage of patients who met the
failure criteria in the WOWO treatment arm. Adhering to a
complicated regimen may have been more difficult, leading to
antiretroviral failure due to poor adherence. Another study that
used the weekly structured treatment interruption strategy had
more success, but the cohort possibly had a shorter duration
of antiretroviral exposure [2]. The use of a triple-drug anti-
retroviral regimen containing efavirenz in a WOWO approach
was successful in a proof-of-concept trial, perhaps indicating
that the longer half-life of non-NRTI may be important for
prevention of intermittent viremia and subsequent develop-
ment of a drug-resistant virus [7]. Finally, the greater number
of visits to the clinic in the WOWO and the CD4 cell count–
guided treatment arms may have had an impact on adherence
and on some outcomes, but this is difficult to conclude with
a small cohort and short study period.
This structured treatment interruption study demonstrates
that all 3 study arms resulted in similar clinical function over
this short follow-up period of up to 48 weeks, with the CD4
cell count–guided and WOWO treatment arms being the most
cost-effective with regard to antiretroviral costs. The immune
function was adequate in all arms if considering the percentage
of patients with a CD4 cell count of 350 cells/mL, whereas
the continuous and WOWO treatment arms were more suc-
cessful than the CD4 cell count–guided treatment arm in main-
taining the CD4 cell count at the baseline level. Calculations
regarding the savings in antiretroviral costs must take into con-
sideration the time that an antiretroviral-naive patient must
take continuous therapy to achieve a plasma viral load of !50
copies/mL. Most patients (78%) in the CD4 cell count–guided
treatment arm had received 12 weeks of re-treatment with
antiretrovirals, thereby reducing some of the expected savings
in antiretroviral-associated costs. Because this study was con-
ducted before current antiretroviral initiation criteria were in
place, these patients started receiving antiretroviral therapy
while they had relatively high CD4 cell counts (100–500 cells/
mL). Because current criteria for initiation of antiretroviral ther-
apy indicate that a patient should begin therapy at relatively
lower CD4 cell counts, this treatment cohort may not be re-
flective of the HIV-infected population in the developing world
who are eligible for treatment. Because most patients in the
CD4 cell count–guided treatment arm required re-treatment,
use of this strategy may be less useful in areas in the developing
world with resource limitations. Additionally, the high CD4 cell
counts before the structured treatment interruption may have
positively influenced the results in the CD4 cell count–guided
treatment arm, which may not occur if a patient began to
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receive treatment with a lower CD4 cell count. The high treat-
ment failure rate in the WOWO arm makes this strategy less
useful in terms of virological control. The use of structured
treatment interruption—in particular, the CD4 cell count–
guided strategy—for virologically well-controlled patients with
shorter (and more optimal) antiretroviral exposure and lower
pre–antiretroviral therapy/pre–structured treatment interrup-
tion CD4 cell counts may prove to be an appropriate HAART
administration strategy that can save costs associated with an-
tiretroviral use, preserve adequate immune function, and pro-
vide comparable safety profiles to continuous HAART therapy.
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